IMAB027

· Ganymed Pharmaceuticals GmbH

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IMAB027, covering 2024-11-21 to 2024-11-21. Get the full timeline:

Most recent: Clinical Trial Update: Phase 1 Trial of IMAB027 in Patients With Recurrent Advanced Ovarian Cancer (OVAR) [Phase 1]